Abstract 3734: Cancer cell-targeted photoimmunotherapy elicits immunogenic cell death and activates the innate and adaptive immune response in the tumor microenvironment

Phase 1/2a, open‐label, multicenter study of RM‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma

“…18 Preclinical cancer models indicate that photoimmunotherapy induces tumor necrosis and immunogenic cell death that can lead to local and systemic induction of innate and adaptive immunity. [19][20][21] RM-1929 photoimmunotherapy is an investigational drug-device combination treatment consisting of a cancer-targeting drug (RM-1929) and a laser device system, which is being developed on the Illuminox™ platform. 22 RM-1929 (cetuximab sarotalocan) 23 comprises cetuximab, an antibody targeting epidermal growth factor receptor (EGFR) that is highly expressed in HNSCC, conjugated with IR700.…”

“… 18 Preclinical cancer models indicate that photoimmunotherapy induces tumor necrosis and immunogenic cell death that can lead to local and systemic induction of innate and adaptive immunity. 19 , 20 , 21 …”